LOW-COST, SEQUENCE-BASED CANCER PHARMACOGENETICS

Information

  • Research Project
  • 6144450
  • ApplicationId
    6144450
  • Core Project Number
    R44CA080566
  • Full Project Number
    2R44CA080566-02
  • Serial Number
    80566
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/1/1999 - 25 years ago
  • Project End Date
    2/28/2002 - 22 years ago
  • Program Officer Name
    SCHLOSS, JEFFERY
  • Budget Start Date
    6/19/2000 - 24 years ago
  • Budget End Date
    2/28/2001 - 23 years ago
  • Fiscal Year
    2000
  • Support Year
    2
  • Suffix
  • Award Notice Date
    6/19/2000 - 24 years ago

LOW-COST, SEQUENCE-BASED CANCER PHARMACOGENETICS

The goal of this project is to develop new techniques for Ultra High Throughput Sequencing to enable rapid, low cost pharmacogenetic analysis of genes involved in cancer susceptibility, progression, and treatment. Overall, a 5-fold reduction in-costs will be achieved compared to "l/4x" ABI sequencing reactions. Part of this cost reduction will be achieved through efficient sample handling of small volume reactions, the remainder will be achieved through reduction in labor and plastic consumables associated with sample preparation and processing. The core of the sample handling system will be a 96-channel device for capillary-based aspiration and delivery that will utilize standard micro-well plates as reagent sources. Once the samples have been processed, they will be returned to micro-well plates for loading onto slab-gel or capillary electrophoresis sequencing instruments. The sample-handling device will have integrated pipetting, thermocycling and purification capabilities. Removal of undesirable contaminants from the thermocycling reaction will be accomplished by means of a novel microdialysis procedure. "Proof of principle" testing of capillary-based thermocycling, and the discovery, testing and initial optimization of the purification technology was performed under Phase I of this study. In Phase II, a small footprint, modular sample processing system will be built, and direct sequencing assays tests for five specific genes involved in cancer susceptibility and drug response will be implemented and executed on a panel of 360 human DNA samples of globally diverse ethnic origin. PROPOSED COMMERCIAL APPLICATIONS: GTC is developing sequence-based pharmacogenetics capabilities to provide accurate, cost effective tests for genes involved in drug metabolism and oncology. The Company is pursuing business opportunities with pharmaceutical companies, linking information on sequence variation with disease states and drug response phenotypes to stratify patient populations for lead optimization and clinical trials.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    447683
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:447683\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    OSCIENT PHARMACEUTICALS CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    WALTHAM
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    024538443
  • Organization District
    UNITED STATES